British Columbia Adds Renflexis, a Remicade Biosimilar for Crohn’s, UC, to Public Drug Plan
News
Renflexis (infliximab-abda), Merck’s biosimilar of Remicade (infliximab), has been added to the public drug plan of the Canadian province of British Columbia. As of Aug. 21, adults and children with Crohn’s ... Read more